When "antibacterial" stops being a selling point and becomes a baseline, the competitive logic in the sanitary pad market is being rewritten by a new group standard. Released in August 2026, T/CIAA 008—2026 for antimicrobial sanitary pads, pantyliners, and period pants introduces, for the first time, the concept of "long-lasting antimicrobial" performance, requiring products to retain their inhibitory effect after simulated use. This means products that rely on simple antimicrobial additives and lose efficacy after a few washes will face elimination, while companies with durable technology gain new room for premium pricing.
Background
The standard is managed by the Zhongguancun HuiZhi Antimicrobial New Materials Industry Technology Innovation Alliance, with drafting units including Henan Shulai Hygiene Products, Guangdong Institute of Microbiology (Guangdong Microbial Analysis and Testing Center), SGS-CSTC Standards Technical Services (Shanghai), and Jinda Nano Technology (Xiamen). The composition of the drafting team—spanning manufacturers, authoritative testing bodies, and antimicrobial material suppliers—indicates that the revision underwent multi-stakeholder negotiation rather than being driven by a single company.
Compared with the 2020 edition, the revision focuses on three areas: in definitions, "bacteriostatic sanitary pads" is expanded to "antimicrobial sanitary pads, pantyliners, and period pants," and a new term "long-lasting antimicrobial (bacteriostatic)" is added; in requirements, the standard fully aligns with GB 15979-2024 "Hygienic Requirements for Disposable Hygiene Products," adjusting antibacterial, bacteriostatic, stability, and toxicological indicators, and adding a long-lasting performance requirement; in test methods, corresponding procedures are modified, including a new test for long-lasting efficacy.
The testing conditions for "long-lasting antimicrobial" are noteworthy: bovine serum albumin is added to the skin-contact surface and placed at (36±1)°C for no less than 8 hours to simulate actual use before evaluating the inhibitory effect. This design directly targets a common industry pain point—many products show impressive antibacterial rates in laboratory tests but lose activity upon contact with bodily fluids. The new standard uses stricter simulation to force companies to pay attention to the durability of antimicrobial agents and their bonding strength with the substrate.
Industrial Impact
For upstream antimicrobial material suppliers, this is a technological watershed. The bovine serum albumin simulation will filter out truly sweat-resistant, moisture-resistant, and temperature-resistant antimicrobial agents, potentially marginalizing silver- or zinc-based products that show large inhibition zones initially but poor durability. Long-lasting technologies such as microencapsulation and covalent grafting will gain greater market share, and companies like Jinda Nano Technology with core R&D capabilities are poised to expand their footprint.
For sanitary pad manufacturers, the revision means dual adjustments in formulation and process. On one hand, they need to re-validate whether existing antimicrobial solutions pass the long-lasting test; if not, they must switch agents or increase dosages, directly raising raw material costs. On the other hand, testing expenses cannot be ignored: each product must undergo antibacterial, bacteriostatic, stability, toxicological, and the new long-lasting efficacy tests, lengthening testing cycles and potentially slowing new product launches.
However, the flip side is that the upgraded standard provides compliant companies with a tool for differentiated competition. When the "antibacterial" label is ubiquitous, consumers find it hard to distinguish authenticity. Under the new standard, "long-lasting" certification becomes a credible trust signal. Brands that pass the new tests first can emphasize "effective after 8 hours of simulated use," which is more persuasive than a vague "99% inhibition" claim and helps raise average selling prices.
For OEM and export-oriented companies, the standard revision may alter order structures. International buyers already impose strict antibacterial requirements on hygiene products. With the alignment to GB 15979-2024, domestic products' test methods are closer to international practices, potentially reducing duplicate testing during export. But in the short term, OEM factories may need to share some testing costs with brand owners, squeezing profit margins, which requires supply chain optimization to absorb.